Literature DB >> 26299464

Rapid Identification of Rectal Multidrug-resistant Escherichia coli Before Transrectal Prostate Biopsy.

Veronika L Tchesnokova1, Linda L Ottley2, Kyoko Sakamoto3, Joshua Fierer4, Evgeni Sokurenko5, Michael A Liss6.   

Abstract

OBJECTIVE: To develop and evaluate a rapid multiplex-quantitative polymerase chain reaction (qPCR) to identify fecal carriers of multidrug-resistant extraintestinal pathogenic Escherichia coli (MDR-ExPEC) clonal groups.
METHODS: Men presenting for transrectal prostate biopsy (TPB) at the San Diego Veterans Affairs Medical Center underwent rectal culture immediately before TPB. Rectal swabs were streaked onto ciprofloxacin-supplemented (4 mg/L) MacConkey agar plates, identified, and susceptibility tested. The same swab was sent to the University of Washington for qPCR test (EST200) targeting 2 major MDR-ExPEC clonal groups--ST131 and ST69--that combined were expected to represent majority of fluoroquinolone (FQ)- and trimethoprim-sulfamethoxazole-resistant E coli. We calculate test characteristics including the area under the receiver operative curve (AUC).
RESULTS: We enrolled 104 men from 11/5/2013 to 6/10/2014. FQ-resistant E coli were cultured from 19.2% (20/104) of rectal swabs, and 26% (27/104) of all swabs were positive for EST200 by PCR. The test characteristics comparing the EST200 to the culture-based detection of FQ resistance were 75%, 86%, 94%, and 56%, respectively. The AUC was 0.84 for the EST200 to detect FQ resistance before TPB.
CONCLUSION: Compared to the reference standard rectal culture, EST200 was able to detect majority of FQ-resistant E coli on rectal swabs before prostate biopsy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26299464      PMCID: PMC4698053          DOI: 10.1016/j.urology.2015.07.008

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  29 in total

1.  Urosepsis and bacteraemia caused by antibiotic-resistant organisms after transrectal ultrasonography-guided prostate biopsy.

Authors:  Paul Hadway; Lucinda K Barrett; David J Waghorn; Kadir Hasan; Amarjit Bdesha; Neil Haldar; John Kelleher
Journal:  BJU Int       Date:  2009-12       Impact factor: 5.588

2.  Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy.

Authors:  Raanan Tal; Pinhas M Livne; Dov M Lask; Jack Baniel
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

Review 3.  Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy.

Authors:  P R Sieber; F M Rommel; V E Agusta; J A Breslin; H W Huffnagle; L E Harpster
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

Review 4.  Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.

Authors:  B Djavan; M Waldert; A Zlotta; P Dobronski; C Seitz; M Remzi; A Borkowski; C Schulman; M Marberger
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

5.  Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.

Authors:  René Raaijmakers; Wim J Kirkels; Monique J Roobol; Mark F Wildhagen; Fritz H Schrder
Journal:  Urology       Date:  2002-11       Impact factor: 2.649

6.  Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy.

Authors:  K A Lindert; J N Kabalin; M K Terris
Journal:  J Urol       Date:  2000-07       Impact factor: 7.450

7.  Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis.

Authors:  Kazuyoshi Shigehara; Tohru Miyagi; Takao Nakashima; Masayoshi Shimamura
Journal:  J Infect Chemother       Date:  2008-02-24       Impact factor: 2.211

8.  Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant gram-negative bacilli: a KONSAR study in 2002.

Authors:  Kyungwon Lee; Young Ah Kim; Yeon Joon Park; Hye Soo Lee; Moon Yeun Kim; Eui Chong Kim; Dongeun Yong; Yunsop Chong
Journal:  Yonsei Med J       Date:  2004-08-31       Impact factor: 2.759

9.  Bacterial sepsis after prostate biopsy--a new perspective.

Authors:  Dirk Lange; Christopher Zappavigna; Reza Hamidizadeh; S Larry Goldenberg; Ryan F Paterson; Ben H Chew
Journal:  Urology       Date:  2009-10-07       Impact factor: 2.649

10.  Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.

Authors:  D A Kapoor; I W Klimberg; G H Malek; J D Wegenke; C E Cox; A L Patterson; E Graham; R M Echols; E Whalen; S F Kowalsky
Journal:  Urology       Date:  1998-10       Impact factor: 2.649

View more
  6 in total

Review 1.  Cutting to the Core of the Issue: Emerging Strategies To Reduce Prostate Biopsy-Related Infections.

Authors:  Robin R Chamberland
Journal:  J Clin Microbiol       Date:  2016-05-04       Impact factor: 5.948

2.  Infectious complications of prostate biopsy: winning battles but not war.

Authors:  Okan Derin; Limírio Fonseca; Rafael Sanchez-Salas; Matthew J Roberts
Journal:  World J Urol       Date:  2020-02-24       Impact factor: 4.226

Review 3.  Urinary Tract Infection: Pathogenesis and Outlook.

Authors:  Lisa K McLellan; David A Hunstad
Journal:  Trends Mol Med       Date:  2016-09-28       Impact factor: 11.951

4.  The Uropathogenic Escherichia coli Subclone Sequence Type 131-H30 Is Responsible for Most Antibiotic Prescription Errors at an Urgent Care Clinic.

Authors:  Veronika Tchesnokova; Kim Riddell; Delia Scholes; James R Johnson; Evgeni V Sokurenko
Journal:  Clin Infect Dis       Date:  2019-02-15       Impact factor: 9.079

5.  High-Resolution Melting Analysis for Rapid Detection of Sequence Type 131 Escherichia coli.

Authors:  Lucas B Harrison; Nancy D Hanson
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Establishment and evaluation of an experimental rat model for high-altitude intestinal barrier injury.

Authors:  Han Luo; Dai-Jun Zhou; Zhang Chen; Qi-Quan Zhou; Kui Wu; Kun Tian; Zhi-Wei Li; Zhen-Liang Xiao
Journal:  Exp Ther Med       Date:  2016-12-29       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.